Welcome to Ophthalmology Clinical Trials
Along with treatment in our ophthalmology clinics, we are also actively involved in clinical research studies.
These studies are varied and can be sponsored by industry, the national institutes of health (NIH), private foundation or by our department.
Studies are led by a faculty member who has an interest in the condition.
Meet our clinical trials team
Our clinical trials office is located at the center for outpatient health within the ophthalmology clinic.
For appointments or other questions on ophthalmology clinical trials, please email DOVSClinicalResearch@email.wustl.edu
For research billing and contract questions, please contact Shonda McDaniel email@example.com
Frequent Questions on Clinical Trials
What is a Clinical Trial?
Clinical trials, also known as research studies or patient studies, are essential in the fight against disease. They determine if new treatments are safe and effective and work better than current treatments. By taking part in an ophthalmology clinical trial, you are adding to our knowledge about eye disease and help improve future treatment.
Why Should I participate in a clinical Trial?
The National Institutes of Health (NIH) has a complied information on what a clinical trial is and why they are important https://www.nih.gov/health-information/nih-clinical-research-trials-you
How am I protected?
Each study goes through a rigorous internal review process. This will be explained in the consent form you will be asked to sign if you want to participate in a study.
I am interested in participating – how do I find a trial?
There are several ways;
- Contact our clinical trial team to see what we are currently involved in
- Join Washington University’s Research Participant Registry and be matched to ongoing studies
- Check out ClinicalTrials.gov – this is a database of privately and publicly funded clinical studies conducted around the world
Ongoing Clinical trials
Please contact our clinical trials team if you are interested in participating in any of these trials. Please note that this list is not exhaustive and is subject to change.
- SEER-2 (RGN-NK-302) study – Andrew Huang MD – Assessment of the safety and efficacy of 0.1% RGN-259 Ophthalmic Solution for the treatment of neurotrophic keratopathy
- TEPEZZA (HZNP-TED-402) study – Steven Couch MD – to evaluate the safety and tolerability of different dosing durations of TEPEZZA.
- VRDN-001 study – Steven Couch MD – a safety, tolerability and efficacy study of VRDN 001 in healthy volunteers and persons with Thyroid Eye Disease (TED)
- Dextenza CLN-0050 Study – Lawrence Tychsen MD – a study assessing the safety and efficacy of Dextenza for the treatment of ocular pain and inflammation following surgery for pediatric cataract.
- ShORe (OPT-302) study – Kisha Piggott MD, PhD – to evaluate the efficiacy and safety of intravitreal OPT-302 in combination with Ranibizumab, compared to Ranibizumab alone in partipants with nAMD
- VGN-TED-301 study – Steven Couch MD– A Phase 2b, Study of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED) (LIDS)
- ASCENT (RGX-314-3101) Study – Kisha Piggott MD, PhD – A Randomized, Partially Masked, Controlled, Phase 3 Clinical Study to Evaluate the Efficacy and Safety of RGX-314 Gene Therapy in Participants with nAMD (ASCENT)
- XEN45 (1924-703-007) study – Erin Sieck MD – Study to Assess Change in Disease Activity and Adverse Events of Ab Externo Approach for Glaucoma Gel Stent (XEN45) Implantation In Participants Aged 45 Years or Older With Open-Angle Glaucoma
- ATS22 Study – Margaret Reynolds MD PhD – A randomized trial to evaluate sequential vs simultaneous spectacles plus patching
- IXT7 study – Margaret Reynolds MD, PhD – Randomized Trial of Full-Time Occlusion Therapy for Intermittent Exotropia in Children
- ADVISE study – James Walsh MD, PhD – Multicenter randomized parallel-treatment, comparative effectiveness trial comparing Adalimumab vs. conventional immunosuppression for uveitis